erlotinib hydrochloride has been researched along with Nervous System Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chmielinska, JJ; Kramer, JH; Mak, IT; Spurney, CF; Weglicki, WB | 1 |
| Cid, NG; Labandeira, CM; Manrique, MCA; Mata, JG; Montes, AF; Núñez, MÁ; Ron, DA; Vera, R | 1 |
1 review(s) available for erlotinib hydrochloride and Nervous System Disorders
| Article | Year |
|---|---|
Maintenance treatment in metastatic colorectal cancer: in search of the best strategy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Erlotinib Hydrochloride; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Maintenance Chemotherapy; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Panitumumab; Withholding Treatment | 2020 |
1 other study(ies) available for erlotinib hydrochloride and Nervous System Disorders
| Article | Year |
|---|---|
Substance P receptor blocker, aprepitant, inhibited cutaneous and other neurogenic inflammation side effects of the EGFR1-TKI, erlotinib.
Topics: Animals; Aprepitant; Drug Eruptions; Erlotinib Hydrochloride; Male; Nervous System Diseases; Neurokinin-1 Receptor Antagonists; Rats; Rats, Sprague-Dawley | 2020 |